Callan JMB Inc. Reports Third Quarter 2026 Financial Results
Callan JMB Inc. announced its financial results for the third quarter of 2026, reporting a loss per share of $0.44 compared to a loss of $0.61 in the same period last year.
Stocks · News reference
Filed: 2026-11-13 AccNo: 0001493152-26-051752 Size: 831 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Callan JMB Inc. announced its financial results for the third quarter of 2026, reporting a loss per share of $0.44 compared to a loss of $0.61 in the same period last year.
CEO Wayne Williams and members of the executive leadership team at Callan JMB Inc. have personally invested $1.5 million in the company's common stock at a premium of $1.10 per share.
Callan JMB Inc. has entered into an agreement to install a production line for Rapid Dose Therapeutics' QuickStrip™ oral thin-film technology, projecting $15 million in revenue over the first 18 months.
Callan JMB has received a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics for installation at its Texas facility. The company projects $15 million in revenue over the next 18 months from this new pharmaceutical manufacturing platform, advancing its strategy to expand domestic pharmaceutical manufacturing and healthcare logistics capabilities.
Gainers GrafTech International (NYSE:EAF) stock moved upwards by 33.1% to $11.32 during Monday's regular session. The company's market cap stands at $200.3 million. The company's, Q3 earnings came out
Rapid Dose Therapeutics has delivered a complete QuickStrip production line to Callan JMB, marking a significant step in their manufacturing collaboration.